News

The investigational oral antiviral therapy from Merck is still awaiting FDA authorization.

The development of these programs are being looked at for private practices in the community settings to try to create better prescribing practices and avoid the potential progression to health care associated infections.

The CDC’s Advisory Committee on Immunization Practices voted to recommend hepatitis B, orthopoxviruses, and Ebola vaccines to certain populations, as well as approving 2022 immunization schedules for children, adolescents, and adults.

The organization is hosting its 9th Annual International C Diff Conference and Health EXPO on Thursday and Friday this week. The conference is virtual and free to the public.

Novavax was approved for their first COVID-19 vaccine EUA in Indonesia, and expects more to follow shortly.

In the latest article from SIDP, here is a look at the use of various intravenous (IV) antimicrobial therapies to address infections in these patients.

Suzan Walters, PhD, discusses her research on the PrEP care continuum among people who inject drugs in rural versus urban settings.

The ACIP considered the benefits of the newly emergency-authorized vaccine versus the risks of COVID-19 in children aged 5-11 years old.

Analyzing the 100 largest zoonotic disease outbreaks, investigators found the most significant drivers to be water contamination, sewage management, weather conditions, and change in vector abundance.

Survey findings show short-term benefits may not translate to long-term optimal outcomes.

Pilot program benefits those in need most, covering potential costs associated with vaccination.

29% of cisgender men who have sex with men acquired HIV despite being designated as “low risk.”

The monoclonal antibody sotrovimab reduced the risk of hospitalization or death by 85% in high-risk patients with mild-to-moderate COVID-19.

A new study in Israel supports the use of a shorter course of antibiotics for the treatment of complicated urinary tract infection in recipients of kidney transplants.

Incidences of Clostridioides difficile infection have risen in recent years, and understanding risk factors can help practitioners address associated mortality, morbidity and health care costs.

In Gilead’s BICSTaR trial of their full HIV treatment regimen Biktarvy, 97% of treatment-naïve adults and 96% of treatment-experienced adults achieved virological suppression after 1 year.

The emergency use authorization (EUA) is based on the vaccine data and the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation.

A new report underscores what early data suggested about disparities in the risk of hospitalization and death from COVID-19.

The Walmart-distributed Better Homes & Gardens aromatherapy spray “Lavender & Chamomile with Gemstones” was identified as causing melioidosis in 4 individuals, 2 of whom died.

COVID-19 patients treated with fluvoxamine had a reduced risk of hospitalization and death.

The latest National Immunization Survey-Child, for children born in 2017- 2018, reveals different rates of vaccination by demographic and disease.

Most COVID-19 infection occurs in household settings, and though vaccinated individuals who contracted the Delta variant recovered more quickly than unvaccinated persons, they had similar peak viral load.

The new AY.4.2 "Delta plus" COVID-19 variant is gaining prevalence abroad and is estimated to be slightly more transmissible.

A new study assessed the vaccine acceptance and access among Black and Latinx communities.

First responders are twice as likely to become infected with COVID-19 in the workplace as health care workers and other essential workers, and this increases significantly after adjusting for cofounding factors.

The once-weekly regimen of islatravir and lenacapavir is Merck and Gilead’s first clinical trial since collaborating to develop long-acting HIV treatment options.

The World Health Organization's (WHO) newly formed Scientific Advisory Group on the Origins of Novel Pathogens (SAGO) will lay the groundwork for future identification of future disease threats.

St. Joseph Mercy Health System launched a program in February to provide infusion of monoclonal antibodies for COVID-19 in patients’ homes.